RevHeart

RevHeart was a Healthtech Solutions subsidiary formed in 2021 to advance research on detection and treatment of myocardial injury, with an initial focus on COVID-related heart muscle injury and cardiomyopathy. Public disclosures described a program combining stem cell and electromagnetic stimulation approaches intended to promote cardiac muscle recovery after injury. The company appears to have been an early-stage, preclinical cardiovascular biotech effort rather than a commercial operating business with a broad disclosed pipeline. Available public information on RevHeart is sparse and largely limited to parent-company press releases and secondary reposts, with little evidence of later standalone operations, financing, clinical activity, or an independent web presence.